BSE filing, NSE: NSIL. Summary written from the filing by ALFA Finder's alert engine.
Nalwa Sons Investments Ltd: key numbers
- Share price
- ₹4,888.00
- Market cap
- ₹2,511 Cr
- Revenue (annual)
- ₹101.2 Cr
- Net profit (annual)
- ₹54.51 Cr
- P/E (TTM)
- 45.3×Sector 19.7×
- Promoter holding
- 55.62%+0.00% QoQ
- FII holding
- 6.04%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nalwa Sons Investments Ltd
All →Nalwa Sons Investments Annual General Meeting
Nalwa Sons Investments Limited held its 55th Annual General Meeting on September 30, 2026. The meeting covered the adoption of financial statements and re-appointment of directors.
Nalwa Sons Investments Annual General Meeting
Nalwa Sons Investments Limited will hold its 55th Annual General Meeting on September 30, 2026. The company has filed its Annual Report for FY 2025-26.
Nalwa Sons Investments Other Announcement
Nalwa Sons Investments Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26.
Nalwa Sons Investments Management Change
Nalwa Sons Investments Limited has re-appointed Mr. Mahender Kumar Goel as Whole Time Director for a term of 60 months, effective from November 30, 2026.
Nalwa Sons Investments Q1 FY27 Results: Net Profit ₹26.7 Cr, Up 3.5% YoY
Nalwa Sons Investments Ltd reported revenue from operations of ₹34.4 Cr (-7.3% YoY) and net profit of ₹26.7 Cr (+3.5% YoY) for Q1 FY27.
- Key figure
- Net profit ₹26.7 Cr · +3.5% YoY
Nalwa Sons Investments Board Meeting Date
Nalwa Sons Investments Limited will hold a board meeting on August 7, 2026. The board will consider and approve unaudited financial results for the June 2026 quarter.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.